{"filings":[{"id":41323,"accession_number":"0001628280-26-034146","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2026-05-12T20:32:48+00:00","items":["5.07","9.01"],"status":"ready","headline":"Avantor stockholders re-elect all nine directors, approve exec pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected, including Gregory Summe with 522M votes for and 78M against.","Advisory vote on 2025 named executive officer compensation passed with 601M for, 18M against.","Stockholders selected 1-year frequency for future advisory votes on exec compensation (605M for).","Ratification of Deloitte & Touche as auditor for 2026 approved with 629M votes for, 8.8M against.","Board adopts annual advisory vote on exec compensation until next required frequency vote in 2032."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94990,"accession_number":"0001628280-26-028078","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor Q1 net sales flat YoY; GAAP EPS $0.06, adj. EPS $0.17; reaffirms FY 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1,581M flat YoY; organic sales down 4.1% due to FX headwind of 4.1%.","GAAP net income $43.3M ($0.06 EPS) vs $64.5M; adjusted net income $114.0M ($0.17 adj. EPS).","Adjusted EBITDA $219.4M (13.9% margin); adjusted operating income $190.6M (12.1% margin).","VWR Distribution segment organic sales -4.8%; Bioscience & Medtech organic sales -2.0%.","Operating cash flow $58.7M; free cash flow $25.2M; adjusted net leverage 3.3x."],"consensus_eps_estimate":0.1601,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":1581400000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94989,"accession_number":"0001628280-26-026905","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avantor names Ludovic Brellier EVP Bioscience & Medtech Products; Gourdier to depart by Dec 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ludovic Brellier appointed EVP, Bioscience & Medtech Products and Chief Transformation Officer effective May 1, 2026.","Brellier joins from Danaher, where he was President of Cytiva’s Hardware Solutions; will lead Revival Management Office.","Current EVP Benoit Gourdier will transition to a support role and depart Avantor no later than December 31, 2026.","Brellier to oversee BMP business growth, operational performance, and enterprise transformation initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94988,"accession_number":"0001628280-26-022575","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avantor CFO Brent Jones to depart by June 24; interim CFO named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO R. Brent Jones resigns to join a non-life-sciences company; effective on or before June 24, 2026.","Steve Eck, current SVP and CAO, appointed interim CFO upon Mr. Jones' departure.","Eck receives extra compensation: $45,000/month and $250K RSU vesting over 3 years.","Avantor reaffirms its FY2026 financial guidance from the February 11, 2026 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107756,"accession_number":"0001628280-26-011727","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K/A","filed_at":"2026-02-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avantor appoints Simon Dingemans to Audit & Finance Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Simon Dingemans elected to Avantor board effective January 2, 2026.","Appointed to Audit & Finance Committee effective February 19, 2026.","Committee assignment fills omitted detail from original December 17, 2025 filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107755,"accession_number":"0001628280-26-011722","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K/A","filed_at":"2026-02-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avantor appoints Sanjeev Mehra to Compensation and Audit Committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sanjeev Mehra elected to Avantor board effective December 4, 2025.","Effective February 19, 2026, Mehra appointed to Compensation & Human Resources Committee and Audit & Finance Committee.","Amendment filed to provide committee assignments omitted from original 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107757,"accession_number":"0001628280-26-007120","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Avantor posts $530M net loss in 2025; Q4 organic sales down 4%; Revival program launched","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $1.66B, organic decline 4%; net income dropped to $52M from $500M; GAAP EPS $0.08.","FY2025 net loss $530M (vs $712M income); adjusted EBITDA $1,069M; adjusted EPS $0.90.","Revival program includes VWR brand relaunch, manufacturing/supply chain improvements, e-commerce upgrades.","Segment realignment to VWR Distribution & Services and Bioscience & Medtech Products effective Q1 2026.","Adjusted net leverage 3.2x; operating cash flow $624M; free cash flow $496M."],"consensus_eps_estimate":0.2208,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":6552200000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124137,"accession_number":"0001628280-25-057805","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avantor appoints former GSK CFO Simon Dingemans to board effective Jan 2, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Simon Dingemans elected to board effective Jan 2, 2026, filling vacancy from Jonathan Peacock's Dec 31, 2025 resignation.","Dingemans served as CFO of GSK (2011-2019) and as Managing Director/Partner at Carlyle Group (2020-2022).","Standard non-employee director compensation: $95K annual cash retainer plus $210K RSU grant vesting May 6, 2026.","Dingemans also serves on boards of Vodafone Group, WPP plc, and Genomics Limited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124136,"accession_number":"0001722482-25-000221","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avantor elects Sanjeev Mehra to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mehra, 66, co-founder and managing partner of Periphas Capital, elected on December 4, 2025.","Served as Goldman Sachs partner (1986-2017) and co-head of Americas Private Equity.","Standard non-employee director comp: $95,000 annual cash retainer plus $210,000 RSU grant.","Term expires at 2026 annual meeting; RSUs vest one year from grant date.","Board determined Mehra meets NYSE independence requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124135,"accession_number":"0001628280-25-051159","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avantor appoints Mary Blenn as EVP and COO; Blenn to lead manufacturing and supply chain","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Blenn appointed EVP and COO effective Nov 10, 2025, reporting to CEO Emmanuel Ligner.","Blenn brings 30+ years experience; most recently SVP Global Operations at Cytiva; prior GE Healthcare.","Compensation: base salary $500k, target bonus 75%, initial equity grant $5M split into 2025/2026 awards.","Filing amends CEO Ligner's education to Licence/Maitrise from Université de Savoie; Lucier appointed to Compensation & HR and Nominating & Governance committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124134,"accession_number":"0001628280-25-046902","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor Q3 net loss $712M on $785M goodwill impairment; sales down 5.3% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1.62B, down 5.3% YoY; organic sales decline 4.7%.","Non-cash goodwill impairment of $785M in Distribution unit; GAAP diluted loss per share $1.04.","Adjusted EBITDA $268M (16.5% margin); adjusted EPS $0.22.","Operating cash flow $207M; free cash flow $172M; adjusted net leverage 3.1x.","Board authorized $500M share repurchase program; CEO cites confidence in growth potential."],"consensus_eps_estimate":0.2291,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":4888600000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.82,"calibrated_materiality_score":0.82,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124133,"accession_number":"0001628280-25-045006","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","1.02","2.03","8.01","9.01"],"status":"ready","headline":"Avantor amends credit agreement, adds $1.4B RCF and €950M term loans; redeems €650M notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $1.4B revolving credit facility (RCF) maturing Oct 2030, plus €400M TLA and €550M TLB (TLB matures Oct 2032).","Proceeds used to refinance existing debt, including repaying ~$208M outstanding under terminated $300M A/R facility.","On Oct 10, 2025, redeemed remaining €250M of 2.625% Senior First Lien Notes due 2025; €400M redeemed Aug 29, 2025.","The Amendment extends RCF maturity to Oct 2030 and adds incremental commitments; interest rate based on benchmark plus margin.","TLB margin set at 2.50% plus benchmark rate; RCF and TLA margins based on leverage grid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124132,"accession_number":"0001628280-25-044871","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avantor chairman Jonathan Peacock to step down Dec 31, 2025; Gregory Summe to succeed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jonathan Peacock informed Avantor he will step down as chairman and board member effective December 31, 2025.","Peacock's departure is not due to any disagreement with the company's operations, policies or practices.","Current board member Gregory L. Summe will serve as chairman from January 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124131,"accession_number":"0001628280-25-043910","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avantor appoints former Life Technologies CEO Gregory Lucier to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elected Gregory Lucier as director effective Oct 3, 2025; term expires at 2026 annual meeting.","Lucier currently serves as Exec Chairman & CEO of Corza Medical; previously CEO of NuVasive and Life Technologies.","Standard non-employee director compensation: annual cash retainer $95,000 plus RSU grant valued at $210,000 (prorated).","Lucier also serves on boards of Maravai LifeSciences and as Chairman of Dentsply Sirona."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140804,"accession_number":"0001722482-25-000200","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avantor elects Emmanuel Ligner as director; he becomes President & CEO on August 18","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Emmanuel Ligner elected to Avantor's Board effective Aug 18, 2025, term through 2026 annual meeting.","Ligner will serve as President and CEO beginning Aug 18, per prior July 21 8-K.","Ligner receives no extra compensation for Board service beyond CEO pay.","No material related-party transactions or arrangements with others regarding selection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140803,"accession_number":"0001722482-25-000188","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor Q2 net sales $1.68B flat organic; GAAP EPS $0.09; names new CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1.68B (-1% reported, flat organic); net income $64.7M vs $92.9M a year ago.","Diluted GAAP EPS $0.09; adjusted EPS $0.24; adjusted EBITDA $279.8M (16.6% margin).","Lab Solutions sales $1.12B (-3% reported, -1% organic); Bioscience Production $561M (+3%, +2% organic).","CEO transition: Emmanuel Ligner named President & CEO effective Aug 18, succeeds Michael Stubblefield.","Operating cash flow $154M; free cash flow $125M; adjusted net leverage 3.2x."],"consensus_eps_estimate":0.2529,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":3264800000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140802,"accession_number":"0001193125-25-161950","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avantor names Emmanuel Ligner as President and CEO effective August 18, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ligner succeeds Michael Stubblefield, who steps down as previously announced.","Ligner brings 30+ years in life sciences; formerly CEO of Cytiva and Cerba HealthCare.","Initial annual base salary £775,000; target bonus 150% of base; one-time equity award $5M.","Eligible for annual equity grant target value $9M starting 2026 under equity plan.","Severance upon involuntary termination: lump-sum $75,000 for repatriation plus standard plan terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158540,"accession_number":"0001722482-25-000143","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Avantor adopts executive severance policy and grants retention RSUs to CFO and other executives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Severance policy for CFO Jones, EVP Gourdier, CLO Sokenu: 12-month salary+target bonus on non-cause termination; 24-month on change-in-control.","Retention RSU awards: 162,866 RSUs each to Jones and Gourdier, 122,149 to Sokenu, vesting on 2nd anniversary.","Annual meeting: all ten directors elected, Deloitte ratified as auditor, say-on-pay approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158539,"accession_number":"0001722482-25-000087","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Avantor CEO Michael Stubblefield to step down upon successor appointment","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stubblefield to step down as CEO and from board; will remain non-executive advisor until Feb 28, 2026.","Transition agreement signed April 24; he continues in current role until successor named or End Date.","Eligible for involuntary separation payments under existing employment agreement if employed through End Date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158538,"accession_number":"0001722482-25-000077","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor Q1 net sales down 6% to $1.58B; organic decline 2%; adjusted EPS $0.23","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1,581.4M (-6% reported, -2% organic); net income $64.5M ($0.09 GAAP EPS); adjusted EPS $0.23.","Lab Solutions sales $1,065M (-8% reported, -3% organic); Bioscience Production $516.4M (-1%, flat organic).","Adjusted EBITDA $269.5M (17.0% margin); operating cash flow $109.3M; free cash flow $82.1M.","Cost transformation target raised to $400M gross run-rate savings by exit 2027; full-year outlook updated for policy headwinds.","Management cites reduced demand in Education & Government end market; net leverage 3.2x."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":1581400000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176931,"accession_number":"0001722482-25-000013","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor Q4 organic growth 1%, adjusted EPS $0.27; full-year adjusted EPS $0.99","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $1.69B, down 2% reported; organic growth 1% with bioprocessing up high-single digits.","Q4 GAAP EPS $0.73 (net income $500.4M); adjusted EPS $0.27; adjusted EBITDA margin 18.2%.","Full-year net sales $6.78B, down 3% reported; organic decline 2%; adjusted EBITDA $1.20B margin 17.7%.","Free cash flow Q4 $222.1M; full-year $768.3M; adjusted net leverage 3.2x as of Dec 31, 2024.","Bioscience Production segment Q4 net sales up 4% organic; Laboratory Solutions down 1% organic."],"consensus_eps_estimate":null,"consensus_eps_actual":1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":6783600000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176930,"accession_number":"0001722482-25-000002","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avantor EVP of Sales Jim Bramwell to retire by June 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jim Bramwell, EVP Sales & Customer Excellence, will retire on or around June 30, 2025.","He intends to pursue a full-time faith-based service opportunity after over 30 years at Avantor.","The company has not yet announced a replacement for his role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193730,"accession_number":"0001722482-24-000171","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Dame Louise Makin elected to Avantor board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elected November 4, 2024 as independent director; term expires at 2025 Annual Meeting.","Former CEO of BTG plc (2004-2019), led transformation and $4.2B sale to Boston Scientific.","Currently non-executive chair of Halma plc, a FTSE 100 life-saving technology group.","Standard non-employee director compensation: $95k annual cash, $210k RSU grant (both prorated for 2024), plus $15k tax stipend.","Fills a vacant Board seat; Board determined she meets NYSE and Exchange Act independence standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193729,"accession_number":"0001722482-24-000161","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor Q3 net sales $1.71B (-0.3%), net income $57.8M, raises FCF guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1,714.4M, down 0.3% reported; organic decline 0.7%; currency tailwind of 0.4%.","GAAP diluted EPS $0.08; adjusted EPS $0.26; adjusted EBITDA $302.5M (17.6% margin).","Lab Solutions sales +1.1% reported (+0.6% organic); Bioscience Production -3.2% (-3.5% organic).","Operating cash flow $244.8M; free cash flow $204.0M; management raised full-year FCF guidance.","Adjusted net leverage 3.8x; bioprocessing outperformance and cost programs ahead of plan."],"consensus_eps_estimate":null,"consensus_eps_actual":0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":5097000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210046,"accession_number":"0001722482-24-000142","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor reports Q2 net sales down 2.4% to $1.70B; GAAP EPS $0.14, adjusted $0.25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1.70B, down 2.4% YoY; organic decline 2.0% after FX impact.","Net income $93M vs ($7.3M) loss Q2 2023; GAAP diluted EPS $0.14, adjusted EPS $0.25.","Adjusted EBITDA $306M (17.9% margin); free cash flow $235M with >100% conversion.","Lab Solutions sales $1,155.7M (-3.2% reported), Bioscience Production $547.1M (-0.5%).","Fiscal 2024 guidance reaffirmed; adjusted net leverage 3.9x as of June 30."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":3382600000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210045,"accession_number":"0001722482-24-000136","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"EVP Europe Frederic Vanderhaegen departs Avantor effective June 30, 2024","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Frederic Vanderhaegen, EVP Europe and NEO, will depart on June 30, 2024.","No successor or reason for departure disclosed in the filing.","His role and responsibilities are assumed by other executives? Not stated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228263,"accession_number":"0001722482-24-000125","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avantor replaces Lab Solutions head; appoints Corey Walker as President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Randy Stone to depart as EVP Laboratory Solutions effective June 30, 2024; involuntary termination without cause.","Corey Walker appointed President of Laboratory Solutions, reporting to CEO Michael Stubblefield, effective immediately.","Walker previously served as EVP at Avantor from 2016-2020 and most recently CEO of ILC Dover.","Company reaffirms fiscal year 2024 guidance as previously stated in Q1 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228262,"accession_number":"0001722482-24-000109","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Avantor shareholders approve officer exculpation amendment, re-elect all nine directors at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to certificate of incorporation for officer exculpation passed with 550.8M for, 59.3M against, 18.6M broker non-votes.","All nine director nominees elected; Gregory Summe received 556.2M for (lowest) and Juan Andres 606.8M for (highest).","Ratification of Deloitte & Touche as auditor for FY 2024: 613.5M for, 15.2M against.","Advisory vote on 2023 executive compensation approved: 569.6M for, 40.5M against, 18.6M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228261,"accession_number":"0001722482-24-000100","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor Q1 net sales fall 5.6% to $1.68B; net income down 50% to $60M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1.68B, -5.6% YoY; organic decline 6.3%. Net income $60M vs $121.5M prior year.","Diluted GAAP EPS $0.09, adjusted EPS $0.22; Adjusted EBITDA $283M.","Laboratory Solutions organic sales -4.5%; Bioscience Production organic -10.0%.","Operating cash flow $142M, free cash flow $107M; FY2024 guidance reaffirmed.","Adjusted net leverage 4.0x as of March 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":1679800000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228260,"accession_number":"0001722482-24-000084","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["1.01","2.03","5.02","9.01"],"status":"ready","headline":"Avantor refinances $772M term loans at lower rate; former EVP to advise","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Refinanced $772.4M Incremental B-6 Dollar Term Loans at SOFR + 2.00% (down from +2.25% on prior loans).","New loans mature Nov 6, 2027, same maturity as refinanced B-5 loans; proceeds used to repay existing B-5 term loans.","Dr. Gerard Brophy, former EVP Biopharma Production, gets consulting deals: $180K/yr cash + $25K/yr + $50K RSU for SAB chair role through Feb 2027.","Consulting agreements include noncompetition, nonsolicitation, and IP assignment provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247000,"accession_number":"0001722482-24-000071","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Avantor board amends bylaws to align with SEC Rule 14a-19 and DGCL changes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendments adopted Feb 23, 2024; effective immediately.","Section 2.03 updated for director nominations and proxy solicitations, requiring compliance with SEC Rule 14a-19.","Removed requirement to produce stockholder list at meetings, conforming to Delaware General Corporation Law.","Section 7.01 clarified indemnification circumstances for indemnitees; ministerial changes also made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246999,"accession_number":"0001722482-24-000014","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Avantor Q4 revenue $1.72B, decline 4%; adjusted EPS $0.25; new segment structure disclosed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $1.72B, down 4.0% YoY; core organic decline 4.8%; Q4 GAAP EPS $0.15, adjusted EPS $0.25.","Full-year 2023 net sales $6.97B, down 7.3%; adjusted EBITDA $1.309B; free cash flow $723.6M.","Repaid ~$850M of debt in 2023; adjusted net leverage 3.9x.","New segment reporting effective Q1 2024: Laboratory Solutions ($4.74B revenue in 2023) and Bioscience Production ($2.23B revenue).","Recast segment data provided for 2021-2023; adjusted operating income for Bioscience Production $601.9M, Laboratory Solutions $668.3M in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":6967200000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264419,"accession_number":"0001722482-23-000207","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avantor realigns into Laboratory Solutions and Bioscience Production; targets $300M in cost savings by 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New segments: Laboratory Solutions (~$4.7B revenue) and Bioscience Production (~$2.3B revenue), effective Q1 2024.","Randy Stone named EVP Laboratory Solutions; Benoit Gourdier EVP Bioscience Production; Jim Bramwell EVP Sales, effective Jan 1, 2024.","Sheri Lewis (EVP Global Supply Chain) and Frederic Vanderhaegen (EVP Europe) to depart in 2024 after transition.","Cost optimization initiative targets $300M run-rate savings by end of 2026 through efficiency, footprint, and procurement.","FY2023 guidance reaffirmed; two years of historical segment data to be provided in February 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264418,"accession_number":"0001722482-23-000196","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor Q3 2023 net sales $1.72B (-7.3%); GAAP EPS $0.16, adjusted EPS $0.25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $108.4M, adjusted net income $171.6M; free cash flow $193M, operating cash flow $230.7M.","Americas sales $1,019.2M (-9.3% reported, -7.9% core organic); Europe sales $579.8M (-2.6% reported, -8.6% core organic); AMEA sales $121.2M (-12.3% reported, -5.4% core organic).","Adjusted EBITDA $317.8M (18.5% margin); Americas EBITDA margin 22.0% (-140bps), Europe 17.7% (-420bps), AMEA 27.9% (+210bps).","Repaid >$650M of debt YTD; adjusted net leverage 3.9X; management cites stable end markets and disciplined execution."],"consensus_eps_estimate":null,"consensus_eps_actual":0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":5244400000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281672,"accession_number":"0001722482-23-000179","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avantor EVP Biopharma Production Gerard Brophy to retire, step down Oct 2, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gerard Brophy will step down as EVP Biopharma Production on October 2, 2023.","He will retire from the company effective February 29, 2024.","After retirement, Brophy will remain Chair of the Scientific Advisory Board and advisor to the company.","Brophy was a named executive officer in Avantor's 2023 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281671,"accession_number":"0001722482-23-000156","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2023-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor Q2 net sales $1.74B, down 8.7%; GAAP EPS ($0.01), adjusted EPS $0.28; net loss $7.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1.74B, core organic decline 6.5%; net loss $7.3M vs income $187.4M YoY.","Diluted GAAP EPS ($0.01), adjusted EPS $0.28; adjusted EBITDA $343.0M, margin 19.7%.","Americas sales $1.0256B (-11.3%); Europe $606.9M (-2.7%); AMEA $111.4M (-14.4%).","Non-cash impairment ~$160M on Ritter assets due to high customer inventory and spending slowdown.","Operating cash flow $168.2M; free cash flow $138.1M; repaid >$400M debt H1; upsized revolver to $975M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":3524200000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281670,"accession_number":"0001193125-23-186313","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avantor appoints R. Brent Jones as CFO effective August 7, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["R. Brent Jones named EVP and CFO, effective Aug 7; replaces Thomas Szlosek who departs Aug 4.","Base salary of $575,000; target bonus 80% of base; $200,000 cash signing bonus with 1-year clawback.","Initial long-term equity grant of $5.125 million: half performance stock units, half stock options.","Future annual LTI target of $2 million, allocated same as other executive leadership team members.","Jones previously CFO at LifeScan Global and Klöckner Pentaplast; over 25 years of life sciences finance experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281669,"accession_number":"0001722482-23-000146","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Avantor refinances credit facility; ups revolving commitments to $975M, maturity 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Obtained $515M refinancing and $460M increase, total new revolving commitments $975M.","New revolving commitments mature June 29, 2028, subject to springing maturity conditions.","Interest rates and commitment fees unchanged from existing revolving commitments.","Existing revolving commitments terminated; outstanding letters of credit deemed issued under new facility.","Amendment entered into on June 29, 2023; lenders received customary fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300588,"accession_number":"0001193125-23-144194","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avantor CFO Thomas Szlosek to depart Aug 2, 2023; FY2023 guidance reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Thomas Szlosek resigns effective August 2, 2023 to join a company outside life sciences.","Szlosek's departure is not due to any disagreement with Avantor's operations, policies, or practices.","Avantor has initiated a search for a new CFO; Szlosek will remain through Q2 earnings announcement.","Company reaffirms fiscal 2023 financial guidance provided on April 28, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300587,"accession_number":"0001722482-23-000103","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Avantor stockholders elect ten directors, ratify auditor, approve advisory compensation at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All ten director nominees elected with strong support; votes for ranged from 546.9M to 581.8M.","Ratification of Deloitte & Touche as auditor for FY2023 passed with 602.6M votes for, 8.4M against.","Advisory vote on named executive officer compensation approved with 506.5M for, 78.2M against.","Broker non-votes of 26.2M on director elections and advisory compensation proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300586,"accession_number":"0001722482-23-000096","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor Q1 net sales $1.78B, down 8.7% YoY; adjusted EPS $0.29","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1.78B, down 8.7% YoY; core organic sales decline 1.8% (ex-COVID).","GAAP net income $121.5M ($0.18 EPS); adjusted net income $195.4M ($0.29 adjusted EPS).","Adjusted EBITDA $346.2M (19.4% margin); free cash flow $191.5M.","Americas sales $1,032.0M (-9.7% reported, core organic -3.7%); Europe $630.2M (-7.4%, +1.0% core); AMEA $118.1M (-6.7%, +1.0% core).","Adjusted net leverage 3.8X; within target range of 2X-4X."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1780300000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320567,"accession_number":"0001722482-23-000028","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2023-02-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor Q4 net sales down 5.9% to $1.80B; core organic growth +2.7%; adj. EBITDA margin 20.0%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS $0.21; adjusted EPS $0.32; net income $141.7M vs $94.0M a year ago.","Full-year net sales $7.51B (+1.7%); core organic growth 6.0%; adj. EBITDA margin 20.9% (+110 bps).","Americas Q4 core organic sales +0.1%; Europe +6.3%; AMEA +5.7%; bioproduction core organic growth >20% in FY.","Adjusted net leverage reduced to 3.7X from 4.2X; free cash flow Q4 $172.0M, FY $710.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":7512400000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338712,"accession_number":"0001722482-22-000193","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avantor director Matt Holt retires from Board effective Nov 16, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matt Holt retired from Avantor's Board effective November 16, 2022.","Retirement was not due to any disagreement with the Company.","No replacement was named in the filing; board size reduced by one."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338711,"accession_number":"0001722482-22-000184","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2022-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor reports Q3 2022 net sales $1.86B, core organic growth 7.8%; adjusted EPS $0.34, updates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1.86B (+1.2% reported); core organic growth 7.8%; net income $167.0M.","Adjusted EBITDA $384.0M, margin 20.7% (up 110 bps); diluted GAAP EPS $0.25, adjusted EPS $0.34.","Americas +7.5% sales, Europe -11.8% (FX impact), AMEA +20.6%; core organic growth 8.8%, 4.8%, 15.1% respectively.","FY 2022 guidance updated: organic growth 2.5-3.0% (6.0-6.5% excl COVID headwinds); adjusted EPS $1.38-$1.40.","Operating cash flow $258.3M, free cash flow $219.3M; net leverage reduced to 3.6X from 3.9X."],"consensus_eps_estimate":null,"consensus_eps_actual":0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":5717400000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356065,"accession_number":"0001722482-22-000170","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2022-09-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Avantor narrows Q3 revenue guidance to ~$1.84-1.85B; cuts acquisition contribution to $400M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 total net sales expected ~$1,840M-$1,850M, including $400M from recent acquisitions (down from $450M).","Core organic net sales growth of 3%-4% in Q3, accelerating from 2.3% in Q2 2022.","Cites FX, COVID headwinds, supply chain constraints, and softening European industrial demand.","H1 2022 delivered ~7% core organic growth, >140 bps Adjusted EBITDA margin expansion, and 13% adj. net income growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356064,"accession_number":"0001722482-22-000162","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2022-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor Q2 beats: EPS $0.37 adjusted, revenue $1.91B, core organic growth 6.4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1.91B (+2.8% reported; core organic +6.4%); adjusted EBITDA $404.1M (+10.2%), margin 21.2% (+140bps).","Diluted GAAP EPS $0.28, adjusted EPS $0.37; net income $187.4M vs $157.8M prior year.","Operating cash flow $227.5M, free cash flow $191.2M; adjusted net leverage reduced to 3.9X.","Americas core organic +8.1%, Europe +4.7%, AMEA -0.3%; segment EBITDA margins all improved.","CEO cites strong bioproduction growth (+20% core organic) and expects continued momentum in H2."],"consensus_eps_estimate":null,"consensus_eps_actual":0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":3860900000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374398,"accession_number":"0001193125-22-153111","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2022-05-17T23:59:59+00:00","items":["3.01","5.03","8.01","9.01"],"status":"ready","headline":"Avantor converts all Series A Preferred Stock to common; preferred delisted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 6.250% Series A Mandatory Convertible Preferred Stock automatically converted to common stock on May 16, 2022.","Conversion rate of 3.0395 common shares per preferred share; cash paid for fractional shares.","No shares of Preferred Stock remain outstanding after conversion.","Company requested NYSE to delist preferred stock and will file Form 15 to suspend reporting obligations.","Certificate of Elimination filed to remove preferred stock terms from corporate charter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374397,"accession_number":"0001722482-22-000121","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2022-05-13T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Avantor stockholders elect all 11 director nominees, ratify Deloitte, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected with majority support; Gregory Summe received fewest for votes (510M for, 26.7M against).","Ratification of Deloitte & Touche as auditor for FY2022 approved with 560.6M votes for, 3.2M against.","Advisory vote on 2021 named executive officer compensation approved with 504.0M for, 32.9M against, 0.4M abstain.","Broker non-votes totaled 26.9M on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374396,"accession_number":"0001722482-22-000112","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2022-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avantor Q1 2022: Net sales $1.95B, adj EPS $0.38, raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $1.95B, organic growth 5.1%; net income $190.4M vs $164.0M prior year.","Diluted GAAP EPS $0.28, adjusted EPS $0.38; adj EBITDA $423.1M (21.7% margin, +140bps YoY).","Americas +10.5%, Europe +4.6%, AMEA +26.6%; bioproduction growth >20%.","Operating cash flow $152.2M, free cash flow $127.7M; net leverage reduced to 4.0X.","Raised full-year adjusted EPS guidance; CEO cites strong execution and investments."],"consensus_eps_estimate":null,"consensus_eps_actual":0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1950400000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392936,"accession_number":"0001722482-22-000033","cik":1722482,"company_name":"Avantor, Inc.","ticker":"AVTR","form_type":"8-K","filed_at":"2022-02-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Avantor Chairman Rajiv Gupta to retire at May 12 annual meeting; board to name successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rajiv Gupta (76) will not stand for re-election; term ends at 2022 annual meeting on May 12, 2022.","Gupta has served as Chairman since August 2010 and is also Senior Advisor to New Mountain Capital.","His decision is not due to any disagreement with Avantor's operations, policies, or practices.","Board plans to announce a new Chair later in February 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6066281196.957738,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-02-15T23:59:59+00:00|392936"}